RPRX - CIK 0001802768
Royalty Pharma plc (RPRX) reported net income of $770.95M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | $770.95M | -10.2% |
| FY 2024 | $858.98M | -24.3% |
| FY 2023 | $1.13B | +2549.5% |
| FY 2022 | $42.83M | -93.1% |
| FY 2021 | $619.73M | -36.4% |
| FY 2020 | $975.04M | -58.5% |
| FY 2019 | $2.35B | +70.5% |
| FY 2018 | $1.38B | - |
Royalty Pharma plc (RPRX) reported net income of $770.95M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2018 and fiscal 2025, Royalty Pharma plc's net income declined from $1.38B to $770.95M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.